Zealand Pharma's stock dropped significantly after reporting that 20% of trial participants discontinued its weight-loss drug due to gastrointestinal side effects.
Related Topics
Source Attribution
This summary was generated by AI based on publicly available information from MarketWatch. For the complete article, please visit the original source. All rights to the original content belong to the respective publisher. Headlines and factual information are presented under fair use for news reporting purposes.
Powered by TrueSay AI
Ask questions about this article in natural language. For example:
AI answers are based on article content. Verify important information.